Correlation Between Aptevo Therapeutics and Cidara Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Aptevo Therapeutics and Cidara Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aptevo Therapeutics and Cidara Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aptevo Therapeutics and Cidara Therapeutics, you can compare the effects of market volatilities on Aptevo Therapeutics and Cidara Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aptevo Therapeutics with a short position of Cidara Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aptevo Therapeutics and Cidara Therapeutics.

Diversification Opportunities for Aptevo Therapeutics and Cidara Therapeutics

-0.77
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Aptevo and Cidara is -0.77. Overlapping area represents the amount of risk that can be diversified away by holding Aptevo Therapeutics and Cidara Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cidara Therapeutics and Aptevo Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aptevo Therapeutics are associated (or correlated) with Cidara Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cidara Therapeutics has no effect on the direction of Aptevo Therapeutics i.e., Aptevo Therapeutics and Cidara Therapeutics go up and down completely randomly.

Pair Corralation between Aptevo Therapeutics and Cidara Therapeutics

Given the investment horizon of 90 days Aptevo Therapeutics is expected to under-perform the Cidara Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Aptevo Therapeutics is 1.16 times less risky than Cidara Therapeutics. The stock trades about -0.09 of its potential returns per unit of risk. The Cidara Therapeutics is currently generating about 0.17 of returns per unit of risk over similar time horizon. If you would invest  1,970  in Cidara Therapeutics on May 6, 2025 and sell it today you would earn a total of  4,308  from holding Cidara Therapeutics or generate 218.68% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy98.41%
ValuesDaily Returns

Aptevo Therapeutics  vs.  Cidara Therapeutics

 Performance 
       Timeline  
Aptevo Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Aptevo Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in September 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Cidara Therapeutics 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Cidara Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Cidara Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Aptevo Therapeutics and Cidara Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Aptevo Therapeutics and Cidara Therapeutics

The main advantage of trading using opposite Aptevo Therapeutics and Cidara Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aptevo Therapeutics position performs unexpectedly, Cidara Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cidara Therapeutics will offset losses from the drop in Cidara Therapeutics' long position.
The idea behind Aptevo Therapeutics and Cidara Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Complementary Tools

Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance